272 related articles for article (PubMed ID: 24400925)
21. Tissue-specific models of spinal muscular atrophy confirm a critical role of SMN in motor neurons from embryonic to adult stages.
Laird AS; Mackovski N; Rinkwitz S; Becker TS; Giacomotto J
Hum Mol Genet; 2016 May; 25(9):1728-38. PubMed ID: 26908606
[TBL] [Abstract][Full Text] [Related]
22. RNA-sequencing of a mouse-model of spinal muscular atrophy reveals tissue-wide changes in splicing of U12-dependent introns.
Doktor TK; Hua Y; Andersen HS; Brøner S; Liu YH; Wieckowska A; Dembic M; Bruun GH; Krainer AR; Andresen BS
Nucleic Acids Res; 2017 Jan; 45(1):395-416. PubMed ID: 27557711
[TBL] [Abstract][Full Text] [Related]
23. Selective Neuromuscular Denervation in Taiwanese Severe SMA Mouse Can Be Reversed by Morpholino Antisense Oligonucleotides.
Lin TL; Chen TH; Hsu YY; Cheng YH; Juang BT; Jong YJ
PLoS One; 2016; 11(4):e0154723. PubMed ID: 27124114
[TBL] [Abstract][Full Text] [Related]
24. The Antisense Transcript SMN-AS1 Regulates SMN Expression and Is a Novel Therapeutic Target for Spinal Muscular Atrophy.
d'Ydewalle C; Ramos DM; Pyles NJ; Ng SY; Gorz M; Pilato CM; Ling K; Kong L; Ward AJ; Rubin LL; Rigo F; Bennett CF; Sumner CJ
Neuron; 2017 Jan; 93(1):66-79. PubMed ID: 28017471
[TBL] [Abstract][Full Text] [Related]
25. Intravenous scAAV9 delivery of a codon-optimized SMN1 sequence rescues SMA mice.
Dominguez E; Marais T; Chatauret N; Benkhelifa-Ziyyat S; Duque S; Ravassard P; Carcenac R; Astord S; Pereira de Moura A; Voit T; Barkats M
Hum Mol Genet; 2011 Feb; 20(4):681-93. PubMed ID: 21118896
[TBL] [Abstract][Full Text] [Related]
26. The Biochemistry of Survival Motor Neuron Protein Is Paving the Way to Novel Therapies for Spinal Muscle Atrophy.
Lomonte P; Baklouti F; Binda O
Biochemistry; 2020 Apr; 59(14):1391-1397. PubMed ID: 32227847
[TBL] [Abstract][Full Text] [Related]
27. Survival motor neuron protein regulates oxidative stress and inflammatory response in microglia of the spinal cord in spinal muscular atrophy.
Ando S; Osanai D; Takahashi K; Nakamura S; Shimazawa M; Hara H
J Pharmacol Sci; 2020 Dec; 144(4):204-211. PubMed ID: 33070839
[TBL] [Abstract][Full Text] [Related]
28. Astrocyte-produced miR-146a as a mediator of motor neuron loss in spinal muscular atrophy.
Sison SL; Patitucci TN; Seminary ER; Villalon E; Lorson CL; Ebert AD
Hum Mol Genet; 2017 Sep; 26(17):3409-3420. PubMed ID: 28637335
[TBL] [Abstract][Full Text] [Related]
29. Molecular therapeutic strategies for spinal muscular atrophies: current and future clinical trials.
Zanetta C; Nizzardo M; Simone C; Monguzzi E; Bresolin N; Comi GP; Corti S
Clin Ther; 2014 Jan; 36(1):128-40. PubMed ID: 24360800
[TBL] [Abstract][Full Text] [Related]
30. Proteomic assessment of a cell model of spinal muscular atrophy.
Wu CY; Whye D; Glazewski L; Choe L; Kerr D; Lee KH; Mason RW; Wang W
BMC Neurosci; 2011 Mar; 12():25. PubMed ID: 21385431
[TBL] [Abstract][Full Text] [Related]
31. Advances and challenges in developing a therapy for spinal muscular atrophy.
Anderton RS; Mastaglia FL
Expert Rev Neurother; 2015; 15(8):895-908. PubMed ID: 26200127
[TBL] [Abstract][Full Text] [Related]
32. What Genetics Has Told Us and How It Can Inform Future Experiments for Spinal Muscular Atrophy, a Perspective.
Blatnik AJ; McGovern VL; Burghes AHM
Int J Mol Sci; 2021 Aug; 22(16):. PubMed ID: 34445199
[TBL] [Abstract][Full Text] [Related]
33. The zinc finger protein ZPR1 is a potential modifier of spinal muscular atrophy.
Ahmad S; Wang Y; Shaik GM; Burghes AH; Gangwani L
Hum Mol Genet; 2012 Jun; 21(12):2745-58. PubMed ID: 22422766
[TBL] [Abstract][Full Text] [Related]
34. A Perturbed MicroRNA Expression Pattern Characterizes Embryonic Neural Stem Cells Derived from a Severe Mouse Model of Spinal Muscular Atrophy (SMA).
Luchetti A; Ciafrè SA; Murdocca M; Malgieri A; Masotti A; Sanchez M; Farace MG; Novelli G; Sangiuolo F
Int J Mol Sci; 2015 Aug; 16(8):18312-27. PubMed ID: 26258776
[TBL] [Abstract][Full Text] [Related]
35. Cellular and molecular approaches to motor neuron therapy in amyotrophic lateral sclerosis and spinal muscular atrophy.
O'Connor DM; Boulis NM
Neurosci Lett; 2012 Oct; 527(2):78-84. PubMed ID: 22579818
[TBL] [Abstract][Full Text] [Related]
36. Translational fidelity of intrathecal delivery of self-complementary AAV9-survival motor neuron 1 for spinal muscular atrophy.
Passini MA; Bu J; Richards AM; Treleaven CM; Sullivan JA; O'Riordan CR; Scaria A; Kells AP; Samaranch L; San Sebastian W; Federici T; Fiandaca MS; Boulis NM; Bankiewicz KS; Shihabuddin LS; Cheng SH
Hum Gene Ther; 2014 Jul; 25(7):619-30. PubMed ID: 24617515
[TBL] [Abstract][Full Text] [Related]
37. An Overview of the Therapeutic Strategies for the Treatment of Spinal Muscular Atrophy.
Li Y; Zeng H; Wei Y; Ma X; He Z
Hum Gene Ther; 2023 Mar; 34(5-6):180-191. PubMed ID: 36762938
[TBL] [Abstract][Full Text] [Related]
38. Cell-Based Therapy for Spinal Muscular Atrophy.
Han F; Ebrahimi-Barough S; Abolghasemi R; Ai J; Liu Y
Adv Exp Med Biol; 2020; 1266():117-125. PubMed ID: 33105498
[TBL] [Abstract][Full Text] [Related]
39. Interaction between alpha-COP and SMN ameliorates disease phenotype in a mouse model of spinal muscular atrophy.
Custer SK; Astroski JW; Li HX; Androphy EJ
Biochem Biophys Res Commun; 2019 Jun; 514(2):530-537. PubMed ID: 31060774
[TBL] [Abstract][Full Text] [Related]
40. Therapeutics development for spinal muscular atrophy.
Sumner CJ
NeuroRx; 2006 Apr; 3(2):235-45. PubMed ID: 16554261
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
